Core Viewpoint - The company, 港通医疗, has shown a mixed financial performance with a notable increase in revenue but a significant decline in net profit, indicating potential challenges in profitability despite growth in sales [1][2]. Company Overview - 港通医疗 specializes in the research, design, manufacturing, integration, and operation services of medical gas equipment and systems, as well as medical clean equipment and systems [1]. - The main products include medical central oxygen supply systems, medical central suction systems, medical air supply systems, medical gas alarm systems, and medical molecular sieve oxygen generation systems, categorized as Class II medical devices [1]. - The company has obtained 25 medical device registration certificates or filing credentials and was the first in China to pass the National Medical Products Administration's review for medical carbon dioxide excipients [1]. Financial Performance - For the third quarter of 2024, the company reported a revenue of 4.92 billion yuan, representing a year-on-year increase of 13.40% [2]. - The net profit for the same period was 20.0463 million yuan, reflecting a year-on-year decrease of 46.99% [2]. - The gross profit margin stood at 20.02% [2]. Market Position - 港通医疗's rolling price-to-earnings (PE) ratio is 26.82, while the average PE ratio for the medical device industry is 45.15, and the median is 28.66 [1][2]. - The company ranks 68th in terms of PE ratio within its industry [1]. Institutional Holdings - As of the third quarter of 2024, 62 institutions hold shares in 港通医疗, with a total of 1.0387 million shares valued at 0.19 billion yuan [1].
港通医疗收盘上涨2.28%，滚动市盈率26.82倍，总市值17.52亿元